Latamolol

Per mL Latanoprost 50 mcg, timolol 5 mg

Reduction of IOP in patients w/ open-angle glaucoma or ocular HTN who are insufficiently responsive to topical β-blockers, prostaglandin analogues, or other IOP-reducing agents & in whom combination therapy is appropriate.

Adult 1 drop into affected eye once daily.

Hypersensitivity to latanoprost, timolol, benzalkonium chloride. Reactive airway disease including severe COPD & presence or history of bronchial asthma. Sinus bradycardia, 2nd-/3rd-degree AV block, overt cardiac failure or cardiogenic shock.

Hepatic & renal impairment. Latanoprost: Possible increased pigmentation of iris & periorbital tissue (eyelid), increased pigmentation & growth of eyelashes may occur. Angle-closure inflammatory or neovascular glaucoma. Bacterial keratitis. Remove contact lenses prior to administration & may be reinserted 15 min after administration. History of intraocular inflammation (iris/uveitis). Do not use in patients w/ active intraocular inflammation. Patients who do not have an intact posterior cap or those w/ risk factors for macular edema. Timolol: May decrease resting & maximal exercise heart rate. History of chronic bronchitis, emphysema. Gradual w/drawal of treatment in elective surgery. Patients w/ DM. Careful management in patients suspected of developing thyrotoxicosis to avoid abrupt w/drawal of β-blockers. Cerebrovascular insufficiency. Use w/ miotic in reducing elevated IOP in angle-closure glaucoma. May potentiate muscle weakness consistent w/ certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness). Long-term treatment. May affect ability to drive & use machines. Pregnancy & lactation. Childn.

Increased iris pigmentation, eye irritation including stinging, burning & itching, eye pain. Latanoprost: Blurred vision, eyelash & vellus hair changes, punctate epithelial erosions, periorbital oedema, iritis/uvetitis, macular oedema, dry eye, keratitis, corneal oedema & erosion, misdirected eyelashes sometimes resulting in eye irritation, iris cyst, photophobia, periorbital & lid changes resulting in deepening of the eyelid sulcus. Timolol: Bradycardia, arrhythmia, hypotension, syncope, heart block, CVA, cerebral ischemia, heart failure, palpitation, cardiac arrest; dizziness, depression, fatigue, lethargy, hallucinations, confusion; ocular irritation including conjunctivitis, blepharitis, keratitis, blepharoptosis, decreased corneal sensitivity, visual disturbances including refractive changes, diplopia, ptosis; bronchospasm (mainly in patients w/ preexisting bronchospastic disease), resp failure, dyspnea; aggravation of myasthenia gravis, alopecia, nausea, localized & generalized rash, urticarial, impotence, decreased libido, masked symptoms of hypoglycemia in diabetics, diarrhea.

Latanoprost: Precipitation w/ thimerosal. Timolol: Possible additive effects & production of hypotension &/or marked bradycardia w/ catecholamine-depleting drugs. May have additive effects on prolonging AV conduction w/ Ca-channel blocking agent & cardiac glycoside. Severe bradycardia may occur w/ verapamil. Sinus bradycardia may occur w/ quinidine.

Antiglaucoma Preparations

S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

D